CG
NAGE

Cutler Group’s Niagen Bioscience NAGE Stock Holding History

Cutler Group’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,400
Closed -$23K – 6506
2021
Q2 		$23K Sell
4,400
-28,400
-87% -$248K ﹤0.01% 3198
2021
Q1 		$78K Buy
+32,800
New +$260K ﹤0.01% 1979
2018
Q2 		– Sell
-1,200
Closed -$2K – 5035
2018
Q1 		$2K Buy
+1,200
New +$6.28K ﹤0.01% 3878

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cutler Group's NAGE Position: Q1 2024 in Review

Cutler Group reduced its Niagen Bioscience (NAGE) stake by 33% in Q1 2024, selling an estimated $16.5K and leaving 17,900 shares worth $62K. The position accounts for 0.02% of the portfolio, ranked #594.

Cutler Group first reported a position in NAGE in Q4 2017 and has held it in 19 quarters since. The position peaked at $497K in Q1 2021. 67 funds tracked by Wall St. Rank hold NAGE as of Q1 2024.

  • Cutler Group held 17,900 shares of Niagen Bioscience worth $62K as of Q1 2024.
  • Cutler Group sold 8,900 Niagen Bioscience shares in Q1 2024, an estimated $16.5K.
  • Niagen Bioscience made up 0.02% of Cutler Group's portfolio in Q1 2024, its #594 holding.
  • Cutler Group first reported a position in Niagen Bioscience in Q4 2017 and has held it in 19 quarters since.
  • Cutler Group's Niagen Bioscience position peaked at $497K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.